DIAGNOSTIC ADJUNCTS TO CYTOPATHOLOGICAL DIAGNOSIS
DIAGNOSTIC ADJUNCTS TO CYTOPATHOLOGICAL DIAGNOSIS
批准号:
6163416
负责人:
A ABATI
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
“免疫细胞化学已被证明是一种有价值的
辅助细胞病理学诊断。细胞病理学
科参与了几个临床相关的研究项目,
其中许多使用细针抽吸(FNA),
免疫细胞化学提供辅助诊断信息
关于各种肿瘤抗原、HLA抗原或
其他标记。这些研究的部分清单包括:(1)
评估在肿瘤细胞中表达CD 22和CD 19的肿瘤细胞百分比。
FNA标本作为使用单克隆抗体的临床试验的一部分
难治性淋巴瘤的治疗;(2)细胞学诊断和
眼淋巴瘤的免疫表型;(3)表征和
一种新的抗恶性肿瘤鼠单克隆抗体的应用
黑色素瘤,MART-1,随后定量MART-1,
来自恶性黑色素瘤患者的FNA,用于治疗
抗MART-1抗体;(4)形态学和免疫细胞化学
骨髓和外周血样本的评估
检测IV期乳腺癌患者的恶性细胞;
(5)细胞学和免疫细胞化学分析
描述了用于鉴别恶性肿瘤的抗体,
腺癌间皮瘤;(6)CD 3定量
恶性黑色素瘤FNA标本中的阳性淋巴细胞
免疫治疗前后的患者;(7)
骨髓和单采标本中的细胞角蛋白抗体,
微小残留病和循环肿瘤细胞诊断
乳腺癌患者。7)免疫细胞化学评价
支气管肺泡灌洗标本中的淋巴细胞群
患者局部暴露于内毒素。. "
英文摘要
"Immunocytochemistry has proved to be a valuable
diagnostic adjunct to cytopathologic diagnosis. The Cytopathology
Section is involved in several clinically-related research projects,
many of which utilize fine needle aspiration (FNA) and
immunocytochemistry to provide ancillary diagnostic information
regarding expression of various tumor antigens, HLA antigens or
other markers. A partial listing of such studies includes: (1)
Evaluation of percent of tumor cells expressing CD22 and CD19 in
FNA specimens as part of a clinical trial using monoclonal antibody
therapy for refractory lymphomas;(2) Cytologic diagnosis and
immunophenotyping of ocular lymphomas; (3) characterization and
application of a novel murine monoclonal antibody for malignant
melanoma, MART-1 with subsequent quantitation of MART-1 in
FNAs from malignant melanoma patients for treatment with
anti-MART-1 antibody; (4) morphologic and immunocytochemical
evaluation of bone marrow and peripheral blood samples for the
detection of malignant cells in patients with stage IV breast cancer;
(5) cytologic and immunocytochemical analysis of recently
describeld antibodies for the differentialtion of malignant
mesothelioma from adenocarcinoma;(6) Quantitation of CD3
positive lymphocytes in FNA specimens in malignant melanoma
patients before and after immunotherapy;(7) utilization of
cytokeratin antibodies in bone marrow and apheresis specimens for
minimal residual disease and circulating tumor cell diagnoses in
breast carcinoma patients.7) immunocytochemical evaluation of
lymphoid populations in bronchoalveolar lavage specimens from
patients subsequent to local exposure to endotoxin. ."
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DIAGNOSTIC ADJUNCTS TO CYTOPATHOLOGICAL DIAGNOSIS
-
批准号:6163249
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
DIAGNOSTIC ADJUNCTS TO CYTOPATHOLOGICAL DIAGNOSIS
-
批准号:2464426
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
CYTOLOGY APPLIED TO HUMAN DIAGNOSTIC AND RESEARCH PROBLEMS
-
批准号:6163244
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
NCI--BREAST FNA CONFERENCE
-
批准号:6163434
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
CYTOLOGY APPLIED TO HUMAN DIAGNOSTIC AND RESEARCH PROBLEMS
-
批准号:6123629
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
NCI--BREAST FNA CONFERENCE
-
批准号:2464549
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
NCI--BREAST FNA CONFERENCE
-
批准号:6163374
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
MORPHOLOGIC, IMMUNOCYTOCHEMICAL AND F.I.S.H. ANALYSES IN CYTOLOGY
-
批准号:3752127
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
CYTOLOGY APPLIED TO HUMAN DIAGNOSTIC AND RESEARCH PROBLEMS
-
批准号:2464421
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
IMMUNOCYTOCHEMICAL/MOLECULAR PATHOLOGY TECHNIQUES APPLIED TO CYTOPATHOLOGY
-
批准号:6163358
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
IMMUNOCYTOCHEMICAL/MOLECULAR PATHOLOGY TECHNIQUES APPLIED TO CYTOPATHOLOGY
-
批准号:6163430
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
MORPHOLOGIC, IMMUNOCYTOCHEMICAL AND FISH ANALYSES IN CYTOLOGY
-
批准号:5201039
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
ANTI B4 BLOCKED RICIN PLUS IFN ALPHA IN RELAPSED REFRACTORYTOPATHOLOGY
-
批准号:2464529
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:A ABATI
-
依托单位:
国内基金
海外基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
-
批准号:61602201
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2016
-
负责人:周雄辉
-
依托单位:
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
-
批准号:81170309
-
项目类别:面上项目
-
资助金额:50.0万元
-
批准年份:2011
-
负责人:颜桥
-
依托单位:
非小细胞肺癌Biomarker的Imaging MS研究新方法
-
批准号:30672394
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2006
-
负责人:陆豪杰
-
依托单位: